// App-Quantinova.ai

: Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Researchers

Presenter

  • Thomas Alexander

Principal Investigators

  • Vinod A. Pullarkat

  • Elias J. Jabbour

  • Seong Lin Khaw

  • Charles G. Mullighan

  • Ashish Bajel

  • Jessica Leonard

  • Robin Norris

  • Jeffrey Rubnitz

  • Susan I. Vear

  • Michelle Schmidt

  • Bo Tong

  • Ying Zhou

  • Jeremy A. Ross

  • Lindsey Rosenwinkel

  • Amanda Jacobson

  • Su Young Kim

  • Wendy Stock

Medical Centers

  • Department of Nutrition, University of North Carolina, Chapel Hill, NC

  • Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA

  • Department of pathology, City of Hope National Medical Center, Duarte, CA.

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Royal Children's Hospital, Melbourne, Victoria, Australia

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Royal Melbourne Hospital, Melbourne, Australia

  • Department of Neurosurgery, Oregon Health and Science University, Portland, OR

  • Cancer and Blood Diseases Institute, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH

  • AbbVie, Inc., North Chicago, IL

  • Department of Medicine, Section of Hematology and Oncology, The University of Chicago, Chicago, IL

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • PEG-asparaginase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • Navitoclax

  • Venetoclax

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03181126

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved